Patents by Inventor Kentaro Sahashi

Kentaro Sahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES
    Publication number: 20230227826
    Abstract: A method for inhibiting expression of an mRNA having an expanded trinucleotide repeat region is provided comprising administering an oligomer comprising a sense strand and an antisense strand wherein: a) the antisense strand comprises a sequence of Formula (I): rGrCrUrGrCrUrGrCX1X2rCrUrGrCrUrGrCrUrG (I), wherein X1 and X2 are each independently selected from rA, rU, rG, rC, UNA-A, UNA-U, UNA-G, and UNA-C and wherein at least one of X1 and X2 is a UNA monomer; b) the oligomer comprises a UNA monomer at the first position at the 5?-end of the sense strand; and the sense strand and the antisense strand each independently include 19-29 monomers. The oligomer can be formulated in a lipid delivery vehicle, and can inhibit expression of Atrophin-1, Huntingtin, Ataxin-1, Ataxin-2, Ataxin-3, Ataxin-7, Alpha1A-voltage-dependent calcium channel subunit, TATA-box binding protein (TBP), Androgen Receptor, PP2A-PR55beta, FMR-1 Protein (FMRP), FMR-2 protein, Frataxin, Dystrophy Protein Kinase (DMPK), or Ataxin-8.
    Type: Application
    Filed: June 17, 2021
    Publication date: July 20, 2023
    Inventors: Kiyoshi TACHIKAWA, Angel I-Jou LEU, Padmanabh CHIVUKULA, Priya Prakash KARMALI, Tomoki HIRUNAGI, Kentaro SAHASHI, Masahisa KATSUNO
  • TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY
    Publication number: 20230045629
    Abstract: Therapeutic methods and medicines may be developed by identifying a gene responsible for progressive supranuclear palsy, as may effective therapeutic methods and medicines. A medicine for progressive supranuclear palsy may contain a compound for inhibiting the expression of a filamin-A gene is provided. Also provided is an assessment system that uses cells expressing filamin-A, which is used in the search for medicaments for progressive supranuclear palsy or their candidates.
    Type: Application
    Filed: January 14, 2021
    Publication date: February 9, 2023
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventors: Masahisa KATSUNO, Koyo TSUJIKAWA, Kentaro SAHASHI
  • OLIGONUCLEOTIDES FOR CONTROLLING TAU SPLICING, AND USES THEREOF
    Publication number: 20210230598
    Abstract: The present invention provides a tau exon 10 skipping-promoting antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 44 in exon 10 of a tau mRNA precursor. In addition, the present invention provides a tau exon 10 skipping-suppressing antisense oligonucleotide containing at least one 2?-O, 4?-C-ethylene-bridged nucleic acid, and a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a region consisting of the nucleotide sequence shown in SEQ ID NO: 45 in intron 10 of a tau mRNA precursor.
    Type: Application
    Filed: July 3, 2019
    Publication date: July 29, 2021
    Applicants: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM, KNC LABORATORIES CO., LTD.
    Inventors: Gen SOBUE, Kentaro SAHASHI, Shinsuke ISHIGAKI, Kuniyuki ENDO, Tsuyoshi FUJIHARA, Masahiro NEYA, Seiji MATSUDA
  • Antisense oligonucleotide controlling expression amount of TDP-43 and use thereof
    Patent number: 11028390
    Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 8, 2021
    Assignees: Osaka University, KNC Laboratories Co., Ltd., Aichi Medical University
    Inventors: Yoshitaka Nagai, Kazuhiro Maeta, Toshihide Takeuchi, Masahiro Neya, Tsuyoshi Fujihara, Seiji Matsuda, Gen Sobue, Shinsuke Ishigaki, Kentaro Sahashi
  • ANTISENSE OLIGONUCLEOTIDE CONTROLLING EXPRESSION AMOUNT OF TDP-43 AND USE THEREOF
    Publication number: 20200165610
    Abstract: The present invention provides a suppression type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in any of SEQ ID NOs: 2-4, and a promotion type antisense oligonucleotide targeting TDP-43 mRNA, containing a nucleotide sequence complementary to a sequence consisting of at least 10 continuous nucleotides in a nucleotide sequence shown in SEQ ID NO: 5.
    Type: Application
    Filed: July 6, 2018
    Publication date: May 28, 2020
    Applicants: OSAKA UNIVERSITY, KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Yoshitaka NAGAI, Kazuhiro MAETA, Toshihide TAKEUCHI, Masahiro NEYA, Tsuyoshi FUJIHARA, Seiji MATSUDA, Gen SOBUE, Shinsuke ISHIGAKI, Kentaro SAHASHI
  • PHENOCOPY MODEL OF DISEASE
    Publication number: 20140298496
    Abstract: Methods and compositions for generating nonhuman disease models through splicing modulation.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 2, 2014
    Applicant: Cold Spring Harbor Laboratory
    Inventors: Adrian Krainer, Kentaro Sahashi